JLL report projects GCC growth in preventive healthcare and personalised medicine investments

Saudi Arabia and the United Arab Emirates continue to dominate the Gulf’s healthcare investment landscape, accounting for nearly 92% of all deals, according to JLL’s latest white paper Navigating the GCC Healthcare Investment Landscape: Trends, Insights, and Future Outlook. Between 2021 and April 2025, investment volumes reached close to 400 transactions.

JLL notes that shifting demographics are fuelling the surge. A health-conscious, tech-savvy youth population is driving demand for preventive care, wellness services and digital health solutions, while a rapidly ageing population is creating growing need for geriatric services and comprehensive chronic disease management.

National transformation programmes—including Saudi Vision 2030 and the UAE Ministry of Health and Prevention’s 2023–2026 Strategy—are further accelerating investment, injecting capital and fostering public–private partnerships. At the same time, digitalisation is reshaping the region’s healthcare ecosystem, with initiatives such as the UAE’s Riayati platform and Saudi Arabia’s unified electronic health records system transforming patient access, efficiency and service delivery.

The report highlights a shift towards patient-centred care, boosting investment in interaction platforms, premium facilities and advanced diagnostic technologies. Demand is also growing in specialised care areas including oncology, fertility, mental health and rehabilitation, as regulators across the GCC standardise care protocols and patient pathways.

Health-tech remains a key focus, with JLL forecasting larger funding rounds for established digital health players and rising M&A activity as incumbents acquire innovative startups. Preventive healthcare and personalised medicine solutions—ranging from genetic testing and longevity-focused clinical programmes to health monitoring technologies and smart coaching platforms—are expected to attract increasing capital.

A deliberate push into domestic biotechnology and pharmaceutical manufacturing is also underway, reflecting national ambitions for self-reliance and long-term growth. Expansion of hospital networks and specialty clinics, particularly centres of excellence, is expected to strengthen access to high-quality care.

JLL adds that rising healthcare costs will accelerate adoption of value-based care models, with investments channelled into technologies and services that deliver measurable outcomes while containing costs. AI and data analytics are set to play a pivotal role, sharpening diagnoses, optimising treatments and driving operational efficiency across the sector.